SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study
Yu‐Yu Hsiao(Taichung Veterans General Hospital), Shih‐Ann Chen(National Yang Ming Chiao Tung University), Shang‐Ju Wu(National Yang Ming Chiao Tung University), Guan‐Yi Li(National Yang Ming Chiao Tung University), Jiunn-Cherng Lin(National Yang Ming Chiao Tung University), Yu‐Cheng Hsieh(National Yang Ming Chiao Tung University), Wei-Lun Lin(National Yang Ming Chiao Tung University), Shu-Fen Chiu(Taichung Veterans General Hospital), Jin-Long Huang(National Yang Ming Chiao Tung University), Ming‐Jen Kuo(National Yang Ming Chiao Tung University), Ching‐Heng Lin(China Medical University), Yu-Shan Chien(National Yang Ming Chiao Tung University), Cheng-Hung Li(National Yang Ming Chiao Tung University), Yun‐Yu Chen(National Chung Hsing University)
Cited by 3
Related Papers
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary
|Journal of Arrhythmia|2017|705
Wave Reflection and Arterial Stiffness in the Prediction of 15-Year All-Cause and Cardiovascular Mortalities
|Hypertension|2010|373
Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?
|Journal of the American College of Cardiology|2015|258